This inventor holds 3 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Gilead Sciences, Inc.. Active years: 2022-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2025
Title: Kae M Bullock: Innovator in MCL1 Inhibitors
Introduction
Kae M Bullock is a prominent inventor based in San Carlos, CA (US). She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of MCL1 inhibitors. With a total of 3 patents to her name, her work is paving the way for advancements in cancer treatment.
Latest Patents
Kae's latest patents focus on processes and intermediates for preparing MCL1 inhibitors. The present disclosures provide methods for preparing MCL1 inhibitors or a salt thereof, along with related key intermediates. These innovations are crucial for enhancing the efficacy of cancer therapies.
Career Highlights
Kae M Bullock is currently employed at Gilead Sciences, Inc., a leading biopharmaceutical company. Her role involves extensive research and development aimed at creating effective treatments for various diseases. Her expertise and dedication have positioned her as a valuable asset in her field.
Collaborations
Kae collaborates with talented professionals, including Katrien Brak and Greg Cizio. These partnerships foster a dynamic environment for innovation and contribute to the success of their projects.
Conclusion
Kae M Bullock's work in developing MCL1 inhibitors showcases her commitment to advancing medical science. Her contributions are vital for the future of cancer treatment and exemplify the impact of dedicated inventors in the pharmaceutical industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile